Minerva Neurosciences Investor Relations Material
Latest events
Q1 2023
Minerva Neurosciences
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Minerva Neurosciences Inc
Access all reports
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company is developing brexanolone (MNRX), which targets all three types of glucocorticoid receptors to treat postpartum depression and infantile spasms in children. It also focuses on the research and development of a pipeline of compounds that modulate GABA receptors or downstream pathways and programs targeting other neurotransmitter systems. Minerva Neurosciences was founded in 2009 and is based in Menlo Park, California.
Latest articles
Four Decades of IPOs: An Overview
An overview of the stock and IPO market from the 80's until today, highlighting important events and trends.
24 Apr 2024
Larry Page: The Mastermind Behind Google
Explore the journey of Larry Page from a tech-savvy youth to co-founding Google and leading Alphabet.
24 Apr 2024
Mark Leonard: The Mysterious Brain Behind Constellation Software
Information about Mark Leonard is scarce, and one of the only ways to “get to know” him is through his shareholder letters. Join us in an attempt to do so.
24 Apr 2024
Ticker symbol
Country
🇺🇸 United States